On Friday, U.S. stocks climbed, in response to the data indicating a strong pace of job creation in January and a raise up in workers’ wages.
Meanwhile, from healthcare sector, Cambrex Corporation (NYSE:CBM), is the top gainer, and added 29.49% to the share, hitting new 52-week high of $30.35, whereas, Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) is among the top loser of the sector, losing -25.05% from the share.
On the other hand, Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), recently hits new 52-week low of $4.34, and is trading at $3.72. Biocept Inc (NASDAQ:BIOC) is the most volatile stock in the meantime, and it remained 9.18% volatile for the week and 14.22% for the month, whereas, Pfizer Inc (NYSE:PFE) is among the most active stock of the session, attaining volume of 18.32M. TrovaGene Inc (NASDAQ:TROV) showed an unusual incline of volume 1.77M, as compared to its average volume of 132,255.00 for the session. Theravance Inc (NASDAQ:THRX), will release their earning report, after the market close today.
Major News: Anthem, Inc. (NYSE:ANTM), recently alerts consumers to protect themselves from scam email campaigns. Individuals who may have been impacted by the cyber attack against Anthem, should be aware of scam email campaigns targeting current and former Anthem members. These scams, designed to capture personal information (known as “phishing”) are designed to appear as if they are from Anthem and the emails include a “click here” link for credit monitoring. These emails are NOT from Anthem.
- DO NOT click on any links in email.
- DO NOT reply to the email or reach out to the senders in any way.
- DO NOT supply any information on the website that may open, if you have clicked on a link in an email.
- DO NOT open any attachments that arrive with email.
Anthem is not calling members regarding the cyber attack and is not asking for credit card information or social security numbers over the phone.
Actinium Pharmaceuticals, (ATNM), TrovaGene, (TROV), Ohr Pharmaceutical, (OHRP), Keryx Biopharmaceuticals, (KERX), Isis Pharmaceuticals, (ISIS), are among the losing healthcare stocks for the midday trade and details about them are given as under:
Actinium Pharmaceuticals, Inc. (NYSE:ATNM), is trading in a 52-week range of $3.61 to $15.00, hitting new 52-week low of $3.61, with shares decline -25.05% at $3.74 during midday trade, soon after a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, recently declared the pricing of an underwritten public offering of an aggregate 4,444,444 shares of its ordinary stock and warrants to purchase an aggregate of 3,333,333 shares of the Company’s ordinary stock at a combined price to the public of $4.50. The shares of ordinary stock and warrants will be offered separately. The warrants will be exercisable for a period of 4 years following the issuance thereof at an exercise price of $6.50 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery at the closing. There is no established public trading market for the warrants and Actinium does not expect a market to develop in the future. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of ordinary stock and warrants to purchase 499,999 shares of ordinary stock solely to cover over-allotments, if any. The offering is predictable to close on or about February 11, 2015, subject to customary closing conditions.
Actinium Pharmaceuticals, Inc. (NYSE:ATNM), is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.
TrovaGene, Inc. (NASDAQ:TROV), dipped -19.49% and is now trading at $4.71, following the news that a developer of cell-free molecular diagnostics, recently declared the pricing of an underwritten public offering of 4,444,444 shares of its ordinary stock. The gross proceeds to Trovagene from this offering are predictable to be about $20 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene. The offering is predictable to close on or about February 11, 2015, subject to customary closing conditions. Trovagene has also granted to the underwriters a 30-day option to purchase from it up to an additional 666,666 shares of its ordinary stock.
Headquartered in San Diego, California, TrovaGene, Inc. (NASDAQ:TROV), is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease administration.
Shares of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), dropped nearly -9.95% to $6.88, soon after an ophthalmology research and development company, declared the pricing of its formerly declared underwritten public offering of 3,703,704 million shares of its ordinary stock at a public offering price of $6.75 per share for gross proceeds of about $25 million, before deducting estimated underwriting discounts and commissions and other estimated offering expenses. Ohr has also granted the underwriters a 30-day option to purchase up to an additional 555,555 shares of ordinary stock from Ohr to cover overallotments, if any, which would result in additional gross proceeds of about $3.8 million if exercised in full. Ohr intends to use the net proceeds from the public offering to fund clinical trials of OHR-102, the development of its preclinical pipeline, and other general corporate purposes. The offering is predictable to close on February 11, 2015, subject to customary closing conditions.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), is an ophthalmology research and development company. The company’s lead product, Squalamine, is presently being studied as an eye drop formulation (OHR-102) in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, counting the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy.
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), showed a negative movement of -8.02% and is now trading at $5.92. The company formerly declared the pricing of an underwritten public offering of ordinary stock comprising of 9,166,667 shares at $12.00 per share, for gross proceeds of $110 million. In connection with this offering, Keryx granted to the underwriters a 30-day option to purchase additional shares of ordinary stock, equal to up to 15% of the number of shares of ordinary stock sold in the offering. Keryx intends to use the net proceeds from the sale of its ordinary stock to fund the ongoing commercialization and development of Auryxia(TM) (ferric citrate) in the US, pre-commercial activities in Europe, to potentially in-license, attain and develop additional drug candidates, and other general corporate purposes.
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company launched its first FDA-approved product, Auryxia, in the United States in December 2014.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), is trading in a 52-week range of $22.25 to $75.24 with shares losing -4.25% at $58.79, as Isis, declared that it has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4Rx. ISIS-BIIB4Rx is a recently identified development candidate designed to inhibit an unrevealed target to treat a neurodegenerative disease. ISIS-BIIB4Rx is the fourth drug to enter development as part of Isis’ broad partnership with Biogen Idec and is a distinct target and disease indication from ISIS-BIIB3Rx, which entered development in late 2014.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline comprises of 34 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, counting neurological disorders, and cancer.
